Attovia Therapeutics, Inc. competitors & alternatives

RAPTBiotechnologyUnited States

68% match

Biotechnology

RAPT Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2015, the public company leverages its proprietary drug discovery platform to develop treatments for inflammatory and immunologic diseases.

AbbraTech Holdings LLCBiotechnologyUnited States

67% match

Biotechnology

AbbraTech Holdings LLC operates a platform technology focused on recombinant antibody discovery, engineering, and validation. The company targets human diseases such as cancer, immune disorders, and viral infections by developing antibodies for difficult-to-reach drug targets through its proprietary Epivolve technology.

Biotechnology

Neomorph is a clinical-stage biotechnology company founded in 2020 and headquartered in San Diego, California. The company pioneers the discovery and development of molecular glue degraders to target and destroy difficult disease-causing proteins.

VALERIO TXALVIO · BiotechFrance

67% matchPublic

Similar biotech company

Valerio Therapeutics is a biotechnology company that develops precision-guided therapeutics for complex and underserved diseases. It utilizes a proprietary V-Body conjugate platform, based on synthetic single-domain antibody libraries, to enable targeted drug delivery and deep tissue penetration.

Atavistik BioBiotechUnited States

67% match

Similar biotech company

Atavistik Bio is a U.S. biotechnology company developing small-molecule medicines by targeting allosteric sites and metabolite-regulated biology, using its chemoproteomics and drug-discovery platform. Its programs are aimed at treating cancer and other serious diseases.

Ditto BiosciencesBiotechUnited States

67% match

Similar biotech company

Ditto Biosciences is a company headquartered in San Francisco, US, that focuses on drug discovery. The company is involved in identifying proteins that could lead to new drugs for patients with autoimmune diseases.

Affibody ABBiotechnologySweden

66% match

Biotechnology

Affibody AB is a Swedish biopharmaceutical company located in Solna that develops next-generation biopharmaceuticals based on its proprietary Affibody technology platform.

Matchpoint Therapeutics Inc.BiotechnologyUnited States

66% matchPrivate

Biotechnology

Matchpoint Therapeutics Inc. discovers and develops precision small molecule medicines utilizing covalent chemistry and chemoproteomics screening to treat immune diseases. The company leverages proprietary screening technologies and machine learning algorithms to expand the druggable proteome and design covalent drug candidates for patients with serious inflammatory and immune conditions.

ALTEOGENBiotechnologySouth Korea

66% match

Biotechnology

Alteogen is a biotechnology company that researches and develops next-generation bio-betters, biosimilars, and proprietary drug delivery platforms, including long-acting technologies, antibody-drug conjugates (ADCs), and subcutaneous injection conversion technologies. The company serves the global pharmaceutical and healthcare industries by developing advanced biologic drugs and platform solutions.

Similar biotech company

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.

AVACTA GROUP PLCAVCT · BiotechAtlanta, United Kingdom

65% matchPublic

Similar biotech company

Avacta Group Plc operates as a clinical-stage biopharmaceutical company, specializing in the development of cancer therapies and diagnostic solutions. These advancements are driven by its proprietary Affimer and pre|CISION technology platforms, with the company's activities spanning the United Kingdom, North America, South Korea, and broader regions of Asia and Europe. Functioning across distinct Diagnostics and Therapeutics segments, Avacta's diagnostic endeavors include crafting bespoke Affimer proteins for customer products, developing internal diagnostic assays such as the AffiDX SARS-CoV-2 rapid antigen test, and supplying Affimer reagents for integration into third-party offerings. Concurrently, its Therapeutics division is dedicated to pioneering novel cancer immunotherapies through the strategic combination of its proprietary technologies. The company maintains a comprehensive network of collaborations, notably including a research partnership focused on its pre|CISION technology, which utilizes a substrate highly sensitive to cleavage by fibroblast activation protein alpha. Further key alliances encompass a drug development collaboration with LG Chem Life Sciences; a strategic partnership with Tufts University School of Medicine to advance Affimer drug conjugate therapies; a licensing agreement with POINT Biopharma Inc. for the creation of tumor-activated radiopharmaceuticals; and a drug development partnership with AffyXell, aimed at developing engineered mesenchymal stem cells for autoimmune disease treatment. Avacta Group Plc was established in 2003 and is headquartered in Wetherby, United Kingdom.

Silverback TherapeuticsBiotechnologyUnited States

65% match

Biotechnology

Silverback Therapeutics, Inc. is a biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop therapeutic products.